Evidence map›Paper›PMID 36717864›Full record

ArticleOrphanet journal of rare diseases2023

What we don't need to prove but need to do in multidisciplinary treatment and care in Huntington's disease: a position paper.

Alzbeta Mühlbӓck, Marleen van Walsem, Martha Nance, Astri Arnesen, Kirsty Page, Alexandra Fisher, Manon van Kampen, Angela Nuzzi, Roy Limpert, Hanne Ludt Fossmo and 3 more

Abstract readConsensus Statement
In one paragraph

Article in Orphanet journal of rare diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Co-Design of a New Integrated Care Model With People Affected by Huntington's Disease: A Mixed Methods Study.Health expectations : an international journal of public participation in health care and health policy · 2026
    Article
  7. Article
  8. Disparities in Huntington's disease care and research.Current opinion in neurology · 2025
    Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alzbeta MühlbӓckDepartment of Neurology, University Ulm, Ulm, Germany.
Marleen van WalsemDepartment of Neurorehabilitation, Oslo University Hospital, Oslo, Norway.
Martha NanceStruthers Parkinson's Center, Golden Valley, Minneapolis, MN, USA.
Astri ArnesenEuropean Huntington Association (EHA), Moerbeke Waas, Belgium.
Kirsty PageInspire Neurocare, Worcester, UK.
Alexandra FisherWest Midlands Huntington's Disease Team, Neuropsychiatry, The Barberry, Birmingham, UK.
Manon van KampenHuntington Expert Centre Atlant, Apeldoorn, The Netherlands.
Angela NuzziRehabilitation Unit DAS, ASL Bari, Bari, Italy.
Roy LimpertDepartment of Neuropsychiatry, Huntington Center South, Kbo-Isar-Amper-Klinikum Taufkirchen, Taufkirchen, Germany.
Hanne Ludt FossmoUnit for Congenital and Hereditary Neuromuscular Disorders (EMAN), Department of Neurology, Oslo University Hospital, Oslo, Norway.
Travis CruickshankCentre for Precision Health, Edith Cowan University, Perth, Australia.
Ruth VeenhuizenHuntington Expert Centre Atlant, Apeldoorn, The Netherlands. r.veenhuizen@atlant.nl.ORCID 0000-0001-5470-3033
Multidisciplinary Care and Treatment Working Group of the European Huntington’s Disease Network

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuntington's disease is a complex neurodegenerative hereditary disease with symptoms in all domains of a person's functioning. It begins after a healthy start in life and leads through the relentless progression over many years to complete care dependency and finally death. To date, the disease is incurable. The long progressive complex nature of the disease demands multiple disciplines for treatment and care of patient and family. These health care providers need inter- and multidisciplinary collaboration to persevere and be efficacious in this devastating disease trajectory. DISCUSSION: The position paper outlines current knowledge and experience alongside the experience and consensus of a recognised group of HD multidisciplinary experts. Additionally the patient's voice is clear and calls for health care providers with a holistic view on patient and family. Building long-term trust is a cornerstone of the network around the patient. This paper describes a managed care network comprising all the needed professionals and services. In the health care system, the role of a central coordinator or case manager is of key importance but lacks an appropriate guideline. Other disciplines currently without guidelines are general practitioners, nurses, psychologists, and social workers. Guidelines for neurologists, psychiatrists, geneticists, occupational therapists, speech and language therapists, physiotherapists, dieticians, and dentists are being discussed. Apart from all these profession-specific guidelines, distinctive inter- and multidisciplinary collaboration requirements must be met. CONCLUSIONS AND RECOMMENDATIONS: The complex nature of Huntington's disease demands multidisciplinary treatment and care endorsed by international regulations and the lay association. Available guidelines as reviewed in this paper should be used, made available by a central body, and updated every 3-5 years. Time needs to be invested in developing missing guidelines but the lack of this 'proof' should not prevent the 'doing' of good care.

Indexed as

Huntington DiseaseConsensusDelivery of Health CareHealth PersonnelHumansCareCase managerGuidelinesHuntington’s diseaseInterdisciplinary teamManaged care networkMultidisciplinary treatmentPosition paper

Identifiers

PMID36717864
PMCPMC9887752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.